You need to enable JavaScript to run this app.
Regulatory Recon: FDA Reviewers Still Skeptical on Sarepta DMD Drug, Slow Sales for PCSK9s Amid Pricing Debate (21 April 2016)
Recon
Regulatory News
Michael Mezher